Prevention and Management of Medicine Shortages in Belgium, France and from The Perspective of the European Union

Abstract

Objectives: Medicine shortages are a global phenomenon. A growing number of reports indicate the problem is increasingly affecting the European pharmaceutical market. The present study aims to investigate the characteristics, determinants, legal aspects and management of medicine shortages in Belgium, France and from the perspective of the European Union. MethOds: A review of scientific and grey literature was performed. The legal framework on European and national level was reviewed. Primary qualitative data was collected through 22 semi-structured interviews with key representatives of health care systems' stakeholders on the national and European level. Results: France reported three times more shortages than Belgium. However, the main therapy area, the major cause and the dynamics of medicine shortages were analogous between the two countries. Determinants of medicine shortages were categorised in manufacturing problems, distribution and supply issues, and economic-related challenges. Manufacturing problems were most frequently reported as the primary cause of medicine shortages. Laws and regulations related to medicine shortages are more extensive in France than Belgium. Several preventive and responsive measures were identified to address such shortages. cOnclusiOns: Although medicine shortages are country-specific, the underlying mechanisms of medicine shortages appear to be similar in Belgium and France. Economic aspects seem to play a central role in the phenomenon of medicine shortages, as it influences stakeholders' business decisions. The impact of the legal framework around medicines on the occurrence of medicine shortages may be limited. Collaboration, communication and coordination are key to any effective approach to address medicine shortages.

Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons and possible solutions to overcome the barriers

“…In the USA, 168 products were listed short due to manufacturing issues 60. Multiple previous studies have reported manufacturing hurdles as one of the reasons of unavailability of medicine in the market 34 38 39 61…”

Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines

“…This was also acknowledged by the World Health Organization, which stated that there are more appropriate pricing mechanisms for off-patent medicines than ERP (18). Similarly, most scientific articles reviewing shortages of generic medicines identify cost-containment measures and policies as the underlying root cause (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33).…”